Background: The benefit of adding Zolbetuximab to the treatment in patients with Claudin-18 isoform 2 (CLDN18.2)-positive, human epidermal growth factor receptor 2-negative, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJ) is not yet fully elucidated.
Methods: We searched PubMed, Embase and Cochrane databases for randomized controlled trials (RCTs) that investigated Zolbetuximab plus chemotherapy versus chemotherapy alone for GC or GEJ adenocarcinoma. We computed hazard-ratios (HRs) or odds-ratios (ORs) for binary endpoints, with 95% confidence intervals (CIs).
Results: Three studies and 1,233 patients were included. Comparing with Zolbetuximab plus chemotherapy versus chemotherapy alone, progression-free survival (PFS) rate (HR 0.64; 95% CI 0.49-0.84; p < 0.01) and overall survival (OS) rate (HR 0.72; 95% CI 0.62-0.83; p < 0.01) were significant in favor of the Zolbetuximab group. Regarding effectiveness, the Objective Response Rate (ORR) was (OR 1.15; 95% CI 0.87-1.53; p = 0.34).
Conclusions: In this comprehensive systematic review and meta-analysis of RCTs, the incorporation of Zolbetuximab alongside chemotherapy offers a promising prospect for reshaping the established treatment paradigms for patients diagnosed with advanced CLDN18.2-positive GC/GEJ cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10882870 | PMC |
| http://dx.doi.org/10.1186/s12885-024-11980-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Zolbetuximab for Unresectable and Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma: A Review of Literature.
Cureus
December 2024
Subir Chowdhury School of Quality and Reliability, Indian Institute of Technology, Kharagpur, IND.
Article Synopsis
- Zolbetuximab is a chimeric monoclonal antibody designed to target the Claudin 18.2 protein, which is overexpressed in certain gastrointestinal cancers, notably gastric and gastroesophageal junction adenocarcinomas.
- This drug initiates an immune response to attack cancer cells when combined with standard chemotherapy regimens, and it has been approved as a first-line treatment for advanced, unresectable cancers in specific patient populations.
- Clinical trials show that zolbetuximab significantly improves progression-free survival and overall survival rates compared to chemotherapy alone, while maintaining a relatively safe profile for patients.
Gastric cancer remains a major global health concern with high incidence and mortality rates, particularly in East Asia. Patients often have poor outcomes due to limited treatment efficacy. Zolbetuximab, a monoclonal antibody targeting claudin 18.
View Article and Find Full Text PDF[A New Molecular Targeted Agent for Gastric Cancer-The Anti-Claudin 18.2 Antibody, Zolbetuximab].
Gan To Kagaku Ryoho
November 2024
Dept. of Gastroenterology Gastrointestinal Oncology, National Cancer Center Hospital East.
The standard first-line treatment for unresectable advanced or recurrent gastric cancer(GC)and gastroesophageal junction cancer(GEJC)has been a platinum doublet chemotherapy. Trastuzumab with chemotherapy is the standard regimen for HER2-positive GC/GEJC. While, for HER2-negative cases, chemotherapy with or without immune checkpoint inhibitors (ICIs)such as nivolumab or pembrolizumab are regarded as the standard therapy.
View Article and Find Full Text PDFEmerging targets in gastric and pancreatic cancer: Focus on claudin 18.2.
Cancer Lett
December 2024
Department of Medicine, Division of Hematology & Oncology, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA, 15213, USA; UPMC Hillman Cancer Center, Pittsburgh, PA, 15213, USA. Electronic address:
Recently, the molecular landscape of gastric and pancreatic cancers has advanced with Claudin 18.2 (CLDN18.2) emerging as a promising therapeutic target.
View Article and Find Full Text PDF[Claudine 18.2: A new therapeutic target in digestive cancers].
Bull Cancer
December 2024
Department of Medical Oncology, hôpital Saint-Antoine, AP-HP, Sorbonne University, Paris, France. Electronic address:
Therapies targeting HER2 and immune checkpoint inhibitors have improved survival in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma, but the prognosis associated with these cancers remains poor. Claudin 18.2 is a tight junction protein expressed in the oeso-gastric mucosa.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!